Patients with diabetes might be better off with a statin than aspirin

Primary prevention specialist mulls the latest evidence

Three major trials of aspirin for primary prevention of cardiovascular events, viewed together, suggest its benefits are largely outweighed by the bleeding risk, according to a leading Harvard specialist.

The results from the three studies should be considered in the context of findings from statin trials, according to Professor Paul Ridker, from the Centre for Cardiovascular Disease Prevention at the Brigham and Women’s Hospital in Boston.

“Beyond diet maintenance, exercise and smoking cessation, the best strategy for the use of aspirin in the primary prevention of